EVOGENE LTD (EVGN) Stock Price & Overview

NASDAQ:EVGN • IL0011050551

Current stock price

0.766 USD
-0.01 (-1.79%)
Last:

The current stock price of EVGN is 0.766 USD. Today EVGN is down by -1.79%. In the past month the price decreased by -2.27%. In the past year, price decreased by -35.08%.

EVGN Key Statistics

52-Week Range0.72 - 2.42
Current EVGN stock price positioned within its 52-week range.
1-Month Range0.737 - 0.8708
Current EVGN stock price positioned within its 1-month range.
Market Cap
6.68M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.17
Dividend Yield
N/A

EVGN Stock Performance

Today
-1.79%
1 Week
-2.79%
1 Month
-2.27%
3 Months
-24.16%
Longer-term
6 Months -39.21%
1 Year -35.08%
2 Years -89.72%
3 Years -87.24%
5 Years -97.80%
10 Years -98.88%

EVGN Stock Chart

EVOGENE LTD / EVGN Daily stock chart

EVGN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to EVGN. When comparing the yearly performance of all stocks, EVGN is a bad performer in the overall market: 90.21% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

EVGN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EVGN Earnings

On March 5, 2026 EVGN reported an EPS of -0.61 and a revenue of 314.00K. The company missed EPS expectations (-130.02% surprise) and beat revenue expectations (11.94% surprise).

Next Earnings DateMay 19, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.61
Revenue Reported314K
EPS Surprise -130.02%
Revenue Surprise 11.94%

EVGN Forecast & Estimates

7 analysts have analysed EVGN and the average price target is 1.79 USD. This implies a price increase of 133.03% is expected in the next year compared to the current price of 0.766.

For the next year, analysts expect an EPS growth of -30.77% and a revenue growth -61.68% for EVGN


Analysts
Analysts82.86
Price Target1.79 (133.68%)
EPS Next Y-30.77%
Revenue Next Year-61.68%

EVGN Financial Highlights

Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS increased by 62.38% compared to the year before.


Income Statements
Revenue(TTM)3.85M
Net Income(TTM)-8.48M
Industry RankSector Rank
PM (TTM) N/A
ROA -42.33%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-1116.67%
Sales Q2Q%-80.51%
EPS 1Y (TTM)62.38%
Revenue 1Y (TTM)-54.73%

EVGN Ownership

Ownership
Inst Owners2.25%
Shares8.72M
Float8.63M
Ins Owners0.96%
Short Float %1.97%
Short Ratio1.5

About EVGN

Company Profile

EVGN logo image Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Company Info

IPO: 2007-06-11

EVOGENE LTD

13 Gad Feinstein Street, Park Rehovot

Rehovot 7414002 IL

CEO: Ofer Haviv

Employees: 117

EVGN Company Website

EVGN Investor Relations

Phone: 97289311900

EVOGENE LTD / EVGN FAQ

Can you describe the business of EVOGENE LTD?

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.


What is the stock price of EVOGENE LTD today?

The current stock price of EVGN is 0.766 USD. The price decreased by -1.79% in the last trading session.


What is the dividend status of EVOGENE LTD?

EVGN does not pay a dividend.


What is the ChartMill technical and fundamental rating of EVGN stock?

EVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Is EVOGENE LTD (EVGN) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EVGN.


How many employees does EVOGENE LTD have?

EVOGENE LTD (EVGN) currently has 117 employees.